IMPACT OF NICORANDIL IN ANGINA: SUBGROUP ANALYSES
Aims: IONA (impact of nicorandil in angina) is a randomised, double blind, placebo controlled trial of nicorandil, with a target dose of 20 mg twice daily. The consistency of benefits seen in subgroups is reported. Methods: The primary composite end point of the study was coronary heart disease deat...
Saved in:
Main Author: | IONA Study Group |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2010-08-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1468 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
STUDY OF EFFECT PREKONDITSIONIRUYUSCHEGO RESVERATROL AND NICORANDIL IN THE CORRECTION OF ADMA-LIKE PRE-ECLAMPSIA
by: V. V. Gureev, et al.
Published: (2016-10-01) -
Clinical and electrocardiographic markers of trimetazide effectiveness in patients with Functional Class II-III effort angina
by: Yu. N. Fedulaev, et al.
Published: (2007-06-01) -
RETRACTED ARTICLE:. WAYS TO IMPROVE TREATMENT EFFICIENCY OF PATIENTS WITH HIGH CARDIOVASCULAR RISK
by: G. A. Baryshnikova, et al.
Published: (2015-09-01) -
Клиническая гастроэнтерология в работах ученых кафедры терапии факультета повышения квалификации и профессиональной переподготовки специалистов СибГМУ за 25 лет ее существования
Published: (2005-03-01) -
The use of TES-therapy in complex the treatment of stable angina II-III functional class
by: E. K. Gordeeva, et al.
Published: (2016-06-01)